Two biomarker tests -- one for blood and the other for stool -- are mainstays in the treatment of inflammatory bowel disease (IBD), but gastroenterologists are hoping to gain even more insight from ...

Objective IBD therapies and treatments are evolving to deeper levels of remission. Molecular measures of disease may augment current endpoints including the potential for less invasive assessments.